ETS rearrangements in prostate cancer

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 393-399

  Rubin, Mark A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ETS; gene fusion; next generation sequencing; prostate cancer; TMPRSS2:ERG; translocation

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR TMPRSS2; UNCLASSIFIED DRUG;

CANCER CLASSIFICATION; CANCER GROWTH; CHROMOSOME TRANSLOCATION; DISEASE COURSE; FUSION GENE; GENE FUSION; GENE IDENTIFICATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SEQUENCE ANALYSIS;

GENE REARRANGEMENT; HUMANS; MALE; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS;

EID: 84860842223     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.145     Document Type: Review

References (80)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648. (Pubitemid 41528150)
2. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
3. Rubin MA, Chinnaiyan AM. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Lab Invest 2006; 86: 1099-1102. (Pubitemid 44624146)
4. Hanauer DA, Rhodes DR, Sinha-Kumar C, Chinnaiyan AM. Bioinformatics approaches in the study of cancer. Curr Mol Med 2007; 7: 133-141. (Pubitemid 46322284)
5. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66: 3396-3400.
6. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458: 97-101.
7. Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 2009; 69: 2734-2738.
8. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
9. Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010; 23: 539-546.
10. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008; 68: 7629-7637.
11. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci USA 2009; 106: 12353-8.
12. Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009; 11: 804-811.
13. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16: 793-798.
14. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008; 13: 519-528. (Pubitemid 351763901)
15. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM et al. TMPRSS2:ERG fusion-Associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337-8341. (Pubitemid 44449140)
16. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008; 14: 3380-3385.
17. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL et al. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882-888. (Pubitemid 47165141)
18. de Marzo AM, Platz EA, Epstein JI, Ali T, Billis A et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006; 30: 1281-1291. (Pubitemid 44454708)
19. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006; 8: 826-832. (Pubitemid 44564838)
20. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590-598.
21. Ahlers CM, Figg WD. ETS-TMPRSS2 fusion gene products in prostate cancer. Cancer Biol Ther 2006; 5: 254-255.
22. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006; 66: 10658-63. (Pubitemid 44876959)
23. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006; 66: 10242-6. (Pubitemid 44799738)
24. Liu W, Chang B, Sauvageot J, Dimitrov L, GielzakMet al. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer 2006; 45: 1018-1032. (Pubitemid 44435536)
25. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006; 45: 717-719. (Pubitemid 43727158)
26. Wang J, Cai Y, Ren C, IttmannM. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66: 8347-8351. (Pubitemid 44449142)
27. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G et al. Duplication of the fusion of TMPRSS2to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27: 253-263.
28. Clark J, Merson S, Jhavar S, Flohr P, Edwards S et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007; 26: 2667-2673. (Pubitemid 46632014)
29. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz Get al. A variant TMPRSS2isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007; 20: 467-473. (Pubitemid 46482370)
30. Nam RK, Sugar L, Wang Z, Yang W, Kitching R et al. Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007; 6: 40-45. (Pubitemid 46294173)
31. Rajput AB, Miller MA, de Luca A, Boyd N, Leung S et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007; 60: 1238-1243. (Pubitemid 350084545)
32. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007; 17: 1033-1036.
33. Yoshimoto M, Ludkovski O, Bayani J, Graham C, Zielenska M et al. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes Cancer 2007; 46: 861-863. (Pubitemid 47106190)
34. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395-3400.
35. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20: 538-544. (Pubitemid 46631996)
36. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-599. (Pubitemid 47206938)
37. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008; 68: 73-80. (Pubitemid 351380107)
38. Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006; 8: 465-469. (Pubitemid 44035330)
39. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: Frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007; 20: 921-928. (Pubitemid 47267823)
40. Setlur SR , Mertz KD, Hoshida Y, Demichelis F, Lupien M et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100: 815-825. (Pubitemid 351809667)
41. Demichelis F, Fall K, Perner S, Andren O, Schmidt F et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-4599. (Pubitemid 47037039)
42. Mehra R, Tomlins SA, Yu J, Cao X, Wang L et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68: 3584-3590.
43. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009; 15: 4706-4711.
44. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007; 13: 5103-5108. (Pubitemid 47502077)
45. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006; 8: 885-888.
46. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3: 94ra72.
47. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-624.
48. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524-526.
49. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-188. (Pubitemid 351240884)
50. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105: 2105-2110. (Pubitemid 351439472)
51. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM et al. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res 2004; 64: 2270-2305. (Pubitemid 38339483)
52. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-355. (Pubitemid 28357906)
53. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451-1460.
54. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrozek K et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 9234-42.
55. Porter CR, Kodama K, Gibbons RP, Correa R Jr, Chun FK et al. 25-year prostate cancer control and survival outcomes: A 40-year radical prostatectomy single institution series. J Urol 2006; 176: 569-574. (Pubitemid 43927880)
56. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long-Term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176: 564-568. (Pubitemid 43927886)
57. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-Term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872-1876. (Pubitemid 37254948)
58. Arora R, Koch MO, Eble JN, Ulbright TM, Li L et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004; 100: 2362-2366. (Pubitemid 38657883)
59. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998; 90: 233-237. (Pubitemid 28114542)
60. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 1991; 146: 1069-1076.
61. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995; 55: 5408-5414.
62. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994; 54: 3273-3277. (Pubitemid 24208941)
63. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51. (Pubitemid 46026500)
64. Clark J, Attard G, Jhavar S, Flohr P, Reid A et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008; 27: 1993-2003. (Pubitemid 351442741)
65. Barry M, Perner S, Demichelis F, Rubin MA. Interfocal heterogeneity for TMPRSS2-ERG fusion in multifocal prostate cancer. Urology 2007; 70: 630-633. (Pubitemid 350030260)
66. Mehra R, Han B, Tomlins SA, Wang L, Menon A et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res 2007; 67: 7991-7995. (Pubitemid 47395131)
67. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008; 68: 645-649. (Pubitemid 351206738)
68. Barrie SE, Potter GA, Goddard PM, Haynes BP, DowsettMet al. Pharmacology of novel steroidal inhibitors of cytochrome P45017a (17a-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994; 50: 267-273. (Pubitemid 24309119)
69. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E et al. Characterization of ERG,AR and PTEN gene status in circulating tumor cells from patients with castrationresistant prostate cancer. Cancer Res 2009; 69: 2912-2918.
70. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-4571.
71. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008 Oct; 7: 3129-3140.
72. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-4283.
73. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566. (Pubitemid 47206930)
74. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q et al. Therapeutic targeting of SPINK1-positive prostate cancer.Sci Transl Med 2011; 72ra17.
75. Mani RS, Chinnaiyan AM. Triggers for genomic rearrangements: Insights into genomic, cellular and environmental influences. Nat Rev Genet 2010; 11: 819-829.
76. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW et al. A topoisomerase IIbetamediated dsDNA break required for regulated transcription. Science 2006; 312: 1798-1802. (Pubitemid 43962898)
77. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42: 668-675.
78. Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 2010; 70: 9544-9548.
79. Lin C, Yang L, Tanasa B, Hutt K, Ju BG et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139: 1069-1083.
80. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326: 1230.